SCHEDULE 13G: UBS Group AG Discloses 5.06% Stake in Renalytix plc Following Credit Suisse Acquisition

UBS Group AG has disclosed a 5.06% beneficial ownership stake in Renalytix plc, holding 16,774,708 ordinary shares, primarily due to its acquisition of Credit Suisse Group AG.

Summary

• UBS Group AG, a financial institution based in Switzerland, has filed a Schedule 13G with the SEC, reporting beneficial ownership of 16,774,708 ordinary shares of Renalytix plc.
• This stake represents 5.06% of Renalytix plc's total outstanding ordinary shares.
• The beneficial ownership was triggered by UBS Group AG's acquisition of Credit Suisse Group AG on June 12, 2023, which resulted in UBS succeeding to all assets and liabilities of Credit Suisse, including its direct and indirect subsidiaries' holdings.
• UBS Group AG holds shared voting power and shared dispositive power over all 16,774,708 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Renalytix plc.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a significant ownership stake. The positive aspect is that a major financial institution holds a substantial position, implying confidence, even if it's a legacy holding from an acquisition.

Positives

• The disclosure of a significant stake (over 5%) by a major global financial institution like UBS Group AG can be perceived as a vote of confidence in Renalytix plc.
• The continuity of this institutional investment, albeit under a new parent entity (UBS taking over Credit Suisse's holdings), suggests a stable long-term holding.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Renalytix plc's future performance or operations, as it is solely a disclosure of beneficial ownership by UBS Group AG.

Management Comments

• The filing includes a certification by UBS Group AG that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer of the securities.

Industry Context

This filing reflects a change in institutional ownership of Renalytix plc's shares, stemming from a major consolidation event within the global financial services sector (UBS's acquisition of Credit Suisse). It indicates the transfer of an existing significant stake rather than a new investment decision based on Renalytix's recent performance. For Renalytix, it means a large institutional holder's shares are now under the umbrella of a different, albeit larger, financial entity.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory disclosure of beneficial ownership exceeding 5%. It does not provide financial or operational results for Renalytix plc, thus no direct comparison to industry standards for company performance can be made.
• The ownership percentage of 5.06% is a significant institutional stake, common for large asset managers or banks holding positions in publicly traded companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder. The continuity of a large institutional stake (transferred from Credit Suisse to UBS) might offer some perception of stability.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is mentioned in this ownership disclosure.

Next Steps

• No specific future actions or milestones for Renalytix plc are mentioned in this ownership disclosure.
• UBS Group AG will continue to report changes in its beneficial ownership as required by SEC regulations.

Key Dates

Keywords

Renalytix plc, UBS Group AG, Credit Suisse, Schedule 13G, Beneficial Ownership, SEC Filing, Ordinary Shares, Institutional Investor, Bank